This HTML5 document contains 67 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00429/identifier/pharmgkb/
n13http://linked.opendata.cz/resource/AHFS/
n9http://linked.opendata.cz/resource/drugbank/company/
foafhttp://xmlns.com/foaf/0.1/
n11http://linked.opendata.cz/resource/drugbank/dosage/
n17http://bio2rdf.org/drugbank:
n10http://linked.opendata.cz/resource/drugbank/drug/DB00429/identifier/kegg-drug/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00429/identifier/drugbank/
admshttp://www.w3.org/ns/adms#
n16http://www.drugs.com/mtm/
n4http://www.rxlist.com/cgi/generic/
n15http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n8http://linked.opendata.cz/resource/drugbank/drug/DB00429/identifier/national-drug-code-directory/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n21http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n5http://linked.opendata.cz/ontology/drugbank/
n6http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n22http://linked.opendata.cz/resource/drugbank/drug/DB00429/identifier/chebi/
n18http://linked.opendata.cz/resource/atc/
n12http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00429
rdf:type
n5:Drug
n5:description
A nonsteroidal abortifacient agent that is effective in both the first and second trimesters of pregnancy. [PubChem]
n5:dosage
n11:271B4C6C-363D-11E5-9242-09173F13E4C5 n11:271B4C6D-363D-11E5-9242-09173F13E4C5 n11:271B4C6E-363D-11E5-9242-09173F13E4C5
n5:group
approved
n5:indication
For aborting pregnancy between the 13th and 20th weeks of gestation as calculated from the first day of the last normal menstrual period and in the following conditions related to second trimester abortion: 1. Failure of expulsion of the fetus during the course of treatment by another method; 2. Premature rupture of membranes in intrauterine methods with loss of drug and insufficient or absent uterine activity; 3. Requirement of a repeat intrauterine instillation of drug for expulsion of the fetus; 4. Inadvertent or spontaneous rupture of membranes in the presence of a previable fetus and absence of adequate activity for expulsion. Also for the treatment of postpartum hemorrhage due to uterine atony which has not responded to conventional methods of management.
n5:manufacturer
n9:271B4C68-363D-11E5-9242-09173F13E4C5 n9:271B4C69-363D-11E5-9242-09173F13E4C5
owl:sameAs
n15:DB00429 n17:DB00429
dcterms:title
Carboprost Tromethamine
adms:identifier
n8:0009-0856-05 n10:D00682 n20:PA164754883 n22:3404 n23:DB00429
n5:mechanismOfAction
Carboprost is a synthetic prostaglandin. It binds the prostaglandin E2 receptor, causing myometrial contractions, casuing the induction of labour or the expulsion of the placenta. Prostaglandins occur naturally in the body and act at several sites in the body including the womb (uterus). They act on the muscles of the womb, causing them to contract.
n5:packager
n9:271B4C66-363D-11E5-9242-09173F13E4C5 n9:271B4C67-363D-11E5-9242-09173F13E4C5
n5:synonym
Methyldinoprost 1,3-Dihydroxy-2-(hydroxymethyl)propan-2-aminium (5Z,9alpha,11beta,13e,15S)-9,11,15-trihydroxy-15-methylprosta-5,13-dien-1-oate Carboprost Carboprost trometamol 15(S)-15-Methyl-pgf2alpha tromethamine salt (15S)-15-Methyl-pgf2alpha tromethamine salt 15(S)-15-Methylprostaglandin F2alpha tromethamine (15S)-15-Methylprostaglandin F2alpha tromethamine
n5:toxicity
Symptoms of overdose include irritation, nausea, vomiting, diarrhea, coughing, dyspnea, asthma, hypertension, flushing, and pyrexia.
n12:hasAHFSCode
n13:76-00-00
n5:synthesisReference
Ming Li, "CRYSTALS OF CARBOPROST TROMETHAMINE AND THE PREPARATION METHOD AS WELL AS THE USES THEREOF." U.S. Patent US20130190404, issued July 25, 2013.
foaf:page
n4:hemabate.htm n16:carboprost.html
n5:IUPAC-Name
n6:271B4C73-363D-11E5-9242-09173F13E4C5
n5:InChI
n6:271B4C79-363D-11E5-9242-09173F13E4C5
n5:Molecular-Formula
n6:271B4C78-363D-11E5-9242-09173F13E4C5
n5:Molecular-Weight
n6:271B4C75-363D-11E5-9242-09173F13E4C5
n5:Monoisotopic-Weight
n6:271B4C76-363D-11E5-9242-09173F13E4C5
n5:SMILES
n6:271B4C77-363D-11E5-9242-09173F13E4C5
n5:Water-Solubility
n6:271B4C71-363D-11E5-9242-09173F13E4C5 n6:271B4C89-363D-11E5-9242-09173F13E4C5
n5:logP
n6:271B4C6F-363D-11E5-9242-09173F13E4C5 n6:271B4C72-363D-11E5-9242-09173F13E4C5 n6:271B4C8B-363D-11E5-9242-09173F13E4C5
n5:logS
n6:271B4C70-363D-11E5-9242-09173F13E4C5
n12:hasATCCode
n18:G02AD04
n5:H-Bond-Acceptor-Count
n6:271B4C7F-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Donor-Count
n6:271B4C80-363D-11E5-9242-09173F13E4C5
n5:InChIKey
n6:271B4C7A-363D-11E5-9242-09173F13E4C5
n5:Polar-Surface-Area--PSA-
n6:271B4C7B-363D-11E5-9242-09173F13E4C5
n5:Polarizability
n6:271B4C7D-363D-11E5-9242-09173F13E4C5
n5:Refractivity
n6:271B4C7C-363D-11E5-9242-09173F13E4C5
n5:Rotatable-Bond-Count
n6:271B4C7E-363D-11E5-9242-09173F13E4C5
n5:affectedOrganism
Humans and other mammals
n5:casRegistryNumber
58551-69-2
n5:containedIn
n21:271B4C6B-363D-11E5-9242-09173F13E4C5 n21:271B4C6A-363D-11E5-9242-09173F13E4C5
n5:Bioavailability
n6:271B4C85-363D-11E5-9242-09173F13E4C5
n5:Ghose-Filter
n6:271B4C87-363D-11E5-9242-09173F13E4C5
n5:MDDR-Like-Rule
n6:271B4C88-363D-11E5-9242-09173F13E4C5
n5:Melting-Point
n6:271B4C8A-363D-11E5-9242-09173F13E4C5
n5:Number-of-Rings
n6:271B4C84-363D-11E5-9242-09173F13E4C5
n5:Physiological-Charge
n6:271B4C83-363D-11E5-9242-09173F13E4C5
n5:Rule-of-Five
n6:271B4C86-363D-11E5-9242-09173F13E4C5
n5:Traditional-IUPAC-Name
n6:271B4C74-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-acidic-
n6:271B4C81-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-basic-
n6:271B4C82-363D-11E5-9242-09173F13E4C5